-
Posted by
Two Blokes May 5 -
Filed in
Stock
-
5 views
Mirum Pharmaceuticals boasts a strong portfolio with LIVMARLI, Ctexli, and Cholbam, as well as two promising pipeline candidates --volixibat and MRM-3379-- both of which carry billion-dollar potential. The company is expected to be cash flow positive by the end of FY 2025, with significant revenue growth projected for 2025 and 2026. Upcoming data presentations and earnings could drive the stock higher, with analysts' price targets ranging from $54 to $74 per share.
